On Nov. 13, 2020, Agilent Technologies announced it had received U.S. Food and Drug Administration (FDA) approval for the use of PD-L1 IHC 22C3 pharmDx as an aid in identifying patients with triple-negative breast cancer (TNBC) for treatment with KEYTRUDAﾮ (pembrolizumab).

PD-L1 IHC 22C3 pharmDx is the only companion diagnostic that was FDA-approved to aid in the identification of TNBC patients for treatment with KEYTRUDA in combination with chemotherapy.